Advertisement

Der Internist pp 224-231 | Cite as

Hypertoniebehandlung heute

  • W. Vetter
  • H. Vetter
  • D. Edmonds
  • P. Greminger
  • W. Siegenthaler
Chapter

Zusammenfassung

Ausgehend von den gesicherten Erkenntnissen durch die Interventionsstudien und auf der Grundlage des heute zur Verfügung stehenden umfangreichen Arsenals von antihypertensiv wirkenden Mitteln wird in straffer Form die aktuelle Hypertoniebehandlung aufgezeigt, in der nichtmedikamentöse Verfahren und die Berücksichtigung der Risikofaktoren weiterhin ihren festen Platz haben und die Stufentherapie selten geworden ist. Demgemäß steht die Basistherapie, und falls diese nicht oder nicht mehr greift, die „gezielte“ oder patientenorientierte Zweierkombination im Mittelpunkt der Erörterungen.

Schlüsselwörter

Essentielle Hypertonie Antihypertensiva Diuretika Beta-Blocker Kalziumantagonisten ACE-Hemmer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ames RP (1986) The effects of antihypertensive drugs on serum lipids and lipoproteins I. Diuretics. Drugs 32:260–278Google Scholar
  2. 2.
    Ames RP (1986) The effects of antihypertensive drugs on serum lipids and lipoproteins II. Non-diuretic drugs. Drugs 32:335–357PubMedCrossRefGoogle Scholar
  3. 3.
    Baum C, Kennedy DL, Forbes MB, Jones JK (1984) Drug use in the United States in 1981. J Am Med Assoc 251:1292CrossRefGoogle Scholar
  4. 4.
    Blaufox MD, Langford HG (1987) Nonpharmacologic therapy of hypertension. In: Kellermann JJ (ed) Bibliotheca Cardiologica Nr. 41. Karger, BaselGoogle Scholar
  5. 5.
    Boman G (1978) Adverse reactions to antihypertensive drugs, reported to the Swedish adverse drug reaction committee. Acta Med Scand [Suppl] 628:25–27Google Scholar
  6. 6.
    Bulpitt CJ, Shipley MJ, Semmence A (1987) The contribution of a moderate intake of alcohol to the presence of hypertension. J Hypertens 5:85–91PubMedCrossRefGoogle Scholar
  7. 7.
    Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman G, Williams GH (1986) The effects of antihypertensive therapy on the quality of life. N Engl J Med 314:1657–1664PubMedCrossRefGoogle Scholar
  8. 8.
    Cypress BK (1982) Medication therapy in office visits for hypertension: national ambulatory medical care surgery, 1980. Maryland: National Center for Health Statistics. Advancedata 80:1Google Scholar
  9. 9.
    Edmonds D, Vetter H, Vetter W (1987) Angiotensin converting enzyme inhibitors in the clinic: Quality of life. J Hyper-tens 5 [Suppl 3]: 31–35CrossRefGoogle Scholar
  10. 10.
    Edmonds D, Knorr M, Greminger P, Frielingsdorf J, Vetter H, Vetter W (1987) ACE inhibitor versus beta-blok-ker in the treatment of essential hypertension. Nephron 47 [Suppl 1]: 90–93PubMedCrossRefGoogle Scholar
  11. 11.
    Edmonds D, Vetter H, Baumgart P, Greminger P, Vetter W (1988). Time and antihypertensive therapy: A pitfall in evaluating side effects of a crossover study. Postgrad Med (in press)Google Scholar
  12. 12.
    Escher M, Heyden S, Christeller S, Gasser JP, Keller H, Ramsler L, Geel O (1974) Hypertonie, Nikotinabusus, Hy-percholesterinämie und Übergewicht bei Schweizer Männern 1973. Schweiz Med Wochenschr 104:1423–1428PubMedGoogle Scholar
  13. 13.
    Fyhrquist F (1986) Clinical pharmacology of the ACE inhibitors. Drugs 32 [Suppl 5]: 33–39PubMedCrossRefGoogle Scholar
  14. 14.
    Guidelines for the treatment of mild Hypertension (1986) Memorandum from the WHO/ISH. Hypertension 8:957–961Google Scholar
  15. 15.
    Hansson L, Henning M (1978) Negative consequences of blood pressure reduction. Acta Med Scand [Suppl] 628:5–99Google Scholar
  16. 16.
    Helgeland A (1980) Treatment of mild hypertension: a five year controlled drug trial. Am J Med 69:725–732PubMedCrossRefGoogle Scholar
  17. 17.
    Hill JF, Bulpitt CJ, Fletscher AE (1985) Angiotensin converting enzyme inhibitors and quality of life: the European trial. J Hypertension 3 [Suppl]: 91–94Google Scholar
  18. 18.
    Hodsman GP, Colin IJ (1987) Angiotensin converting enzyme inhibitors: Drug interactions. J Hypertens 5:1–6PubMedCrossRefGoogle Scholar
  19. 19.
    Holzgreve H (1988) Milde Hypertonie — eine kritische Analyse der Interventionsstudien. Internist 29:232–238PubMedGoogle Scholar
  20. 20.
    Hypertension Detection and Follow-up Program Cooperative Group (1982) Five-year findings of the hypertension detection and follow-up program. J Am Med Assoc 247:633–638CrossRefGoogle Scholar
  21. 21.
    Kaplan NM (1986) Problems with the use of diuretics in the treatment of hypertension. Am J Nephrol 6:1–5PubMedCrossRefGoogle Scholar
  22. 22.
    Ledingham JGG (1987) Severe hypertension — is there a drug of choice? Nephron 47 [Suppl 1]: 47–50PubMedCrossRefGoogle Scholar
  23. 23.
    Lüscher T, Siegenthaler W, Vetter W (1984) Alkohol und Hypertonic Schweiz Rundschau Med Prax 73:591–595Google Scholar
  24. 24.
    Management Committee (1980) The Australian therapeutic trial in mild hypertension. Lancet 1:1261–1267Google Scholar
  25. 25.
    Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. Br Med J 291:97–104CrossRefGoogle Scholar
  26. 26.
    Meili F, Hany St, Greminger P, Bill W, Vetter W (1985) Blutdruckmessung in Kombination mit einer Schirmbilduntersuchung. Schweiz Rundschau Med Prax 74:1141–1144Google Scholar
  27. 27.
    Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial: risk factor changes and mortality results. J Am Med Assoc 248:1465–1477CrossRefGoogle Scholar
  28. 28.
    Murphy MB, Dollery C (eds) (1983) Calcium antagonists in the treatment of hypertension. Proceedings of a symposium held in Scheveningen, The Netherlands. Hypertension 5:1–125Google Scholar
  29. 29.
    Stephan E (1979) Kombination Schirmbild — Blutdruckmessung. Schweiz Med Wochenschr 109:234–243PubMedGoogle Scholar
  30. 30.
    Stieber J, Döring A, Keil U (1982) Häufigkeit, Bekanntheits- und Behandlungsgrad der Hypertonie in einer Großstadtbevölkerung. MMW 124:747–752Google Scholar
  31. 31.
    Rüssel Gl, Swart S, Bing R, Thurston H, Surales JD (1980) Prazosin and hydralazine in resistant hypertension. Lancet 1:543Google Scholar
  32. 32.
    The IPPPSH Collaborative Group (1985) Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker Oxprenolol: The international prospective primary prevention study in hypertension (IPPPSH). J Hypertens 3:379–392CrossRefGoogle Scholar
  33. 33.
    Todd PA, Rennie CH (1986) Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31:198–248PubMedCrossRefGoogle Scholar
  34. 34.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures av-ering 115 through 129 mmHg. J Am Med Assoc 202:116–122CrossRefGoogle Scholar
  35. 35.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents (1979) Effects of treatment on morbidity in hypertension: II Results in patients with diastolic blood pressure avering 90 through 114 mmHg. J Am Med Assoc 213:1143–1152Google Scholar
  36. 36.
    Vetter H, Vetter W (1986) Praktische Hypertonie, 2. überarb. Aufl. Thieme, StuttgartGoogle Scholar
  37. 37.
    Vetter W, Vetter H (1985) Rationelle Therapie der Hypertonie. Schweiz Rundschau Med Prax 74:1355–1360Google Scholar
  38. 38.
    Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, Hörnkvist PE, Pennert K, Tuomilehto J, Wedel H (1987) Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial. J Hypertension 5:561–572CrossRefGoogle Scholar
  39. 39.
    Williams GH, Croog SH, Levine S, Testa MA, Sudilovsky A (1987) Impact of antihypertensive therapy on quality of life: Effect of hydrochlorothiazide. J Hypertens 5 [Suppl 1]: 29–35Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • W. Vetter
    • 1
    • 3
  • H. Vetter
    • 2
  • D. Edmonds
    • 1
  • P. Greminger
    • 1
  • W. Siegenthaler
    • 1
  1. 1.Departement für Innere Medizin, Medizinische PoliklinikUniversitätsspital ZürichSchweiz
  2. 2.Medizinische Universitäts-Poliklinik BonnDeutschland
  3. 3.Departement für Innere Medizin Medizinische PoliklinikUniversitätsspitalZürichSchweiz

Personalised recommendations